A further observation on sperm structure in a Heterodera sp.

RESP-873

Partitioning 3-homogeneous latin bitrades

A latin bitrade $(T^{\diamond}, T^{\otimes})$ is a pair of partial latin squares which defines the difference between two arbitrary latin squares $L^{\diamond} \supseteq T^{\diamond}$ and $L^{\diamond} \supseteq T^{\otimes}$ of the same order. A 3-homogeneous bitrade $(T^{\diamond}, T^{\otimes})$ has three entries in each row, three entries in each column, and each symbol appears three times in $T^{\diamond}$. Cavenagh (2006) showed that any 3-homogeneous bitrade may be partitioned into three transversals. In this paper we provide an independent proof of Cavenagh's result using geometric methods. In doing so we provide a framework for studying bitrades as tessellations of spherical, euclidean or hyperbolic space.Comment: 13 pages, 11 figures, fixed the figures. Geometriae Dedicata, Accepted: 13 February 2008, Published online: 5 March 200

Integral Field Spectroscopy of a peculiar Supernova Remnant MF16 in NGC6946

We present a study of a peculiar Supernova Remnant MF16, associated with the Ultraluminous X-ray Source (ULX) NGC6946 ULX-1. Observations were taken with the MultiPupil Fiber Spectrograph (MPFS) with 6-m telescope on January 2005. The nebula is found to be highly asymmetric, one of the parts being much denser and colder. The two-component structure of the emission lines and radial velocity gradient argue for a non-spherical nebula, expanding with a velocity of about 100 km/s. Neither shock models nor the X-ray emission can adequately explain the actual emission line spectrum of MF16, so we suggest an additional ultraviolet source with a luminosity of about 10E40 erg/s. We confirm coincidence of the ULX with the central star, and identify radio emission observed by VLA with the most dense part of the nebula.Comment: Proceedings of the ESO and Euro3D Workshop "Science Perspectives for 3D Spectroscopy", Garching (Germany), October 10-14, 2005. M. Kissler-Patig, M.M. Roth and J.R. Walsh (eds.

Measurement of residual stresses induced by sequential weld buttering and cladding operations involving a 2.25Cr-1Mo substrate material

Dissimilar metal welds are necessary in high-pressure subsea systems and in cases where forged components must be welded to pipelines. F22 (2.25Cr-1Mo) steel is often used in such forged steel components and, since this steel cannot enter service without undergoing post-weld heat treatment (PWHT), the components are usually prepared for field welds through the application of a buttering layer. Furthermore, a weld overlay is deposited for the purpose of mitigating corrosion. This combination of multiple welding tasks and dissimilar materials leads to the possibility of developing substantial residual stresses. This study aims to provide insights to the evolution of residual stresses at each stage of the welding operation. The assessment has been undertaken on laboratory-scale weld mock-ups using the contour method for residual stress measurement, and incremental centre hole drilling. It was found that both buttering and cladding introduce near-yield levels of tensile residual stresses, but that these stresses are successfully relieved upon PWHT

Multibeam Maser Survey of methanol and excited OH in the Magellanic clouds: new detections and maser abundance estimates

‘The definitive version is available at www.blackwell-synergy.com.’ Copyright Blackwell Publishing DOI: 10.1111/j.1365-2966.2008.12888.xPeer reviewe

Allocation in Practice

How do we allocate scarcere sources? How do we fairly allocate costs? These are two pressing challenges facing society today. I discuss two recent projects at NICTA concerning resource and cost allocation. In the first, we have been working with FoodBank Local, a social startup working in collaboration with food bank charities around the world to optimise the logistics of collecting and distributing donated food. Before we can distribute this food, we must decide how to allocate it to different charities and food kitchens. This gives rise to a fair division problem with several new dimensions, rarely considered in the literature. In the second, we have been looking at cost allocation within the distribution network of a large multinational company. This also has several new dimensions rarely considered in the literature.Comment: To appear in Proc. of 37th edition of the German Conference on Artificial Intelligence (KI 2014), Springer LNC

On a stochastic partial differential equation with non-local diffusion

In this paper, we prove existence, uniqueness and regularity for a class of stochastic partial differential equations with a fractional Laplacian driven by a space-time white noise in dimension one. The equation we consider may also include a reaction term

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).

OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive (COAST-V) or tumour necrosis factor inhibitor (TNFi)-experienced (COAST-W). METHODS: Adults with active r-axSpA were randomised 1:1:1:1 (n=341) to 80 mg ixekizumab every 2 (IXE Q2W) or 4 weeks (IXE Q4W), placebo (PBO) or 40 mg adalimumab Q2W (ADA) in COAST-V and 1:1:1 (n=316) to IXE Q2W, IXE Q4W or PBO in COAST-W. At week 16, patients receiving ixekizumab continued their assigned treatment; patients receiving PBO or ADA were rerandomised 1:1 to IXE Q2W or IXE Q4W (PBO/IXE, ADA/IXE) through week 52. RESULTS: In COAST-V, Assessment of SpondyloArthritis international Society 40 (ASAS40) responses rates (intent-to-treat population, non-responder imputation) at weeks 16 and 52 were 48% and 53% (IXE Q4W); 52% and 51% (IXE Q2W); 36% and 51% (ADA/IXE); 19% and 47% (PBO/IXE). Corresponding ASAS40 response rates in COAST-W were 25% and 34% (IXE Q4W); 31% and 31% (IXE Q2W); 14% and 39% (PBO/IXE). Both ixekizumab regimens sustained improvements in disease activity, physical function, objective markers of inflammation, QoL, health status and overall function up to 52 weeks. Safety through 52 weeks of ixekizumab was consistent with safety through 16 weeks. CONCLUSION: The significant efficacy demonstrated with ixekizumab at week 16 was sustained for up to 52 weeks in bDMARD-naive and TNFi-experienced patients. bDMARD-naive patients initially treated with ADA demonstrated further numerical improvements after switching to ixekizumab. Safety findings were consistent with the known safety profile of ixekizumab. TRIAL REGISTRATION NUMBER: NCT02696785/NCT02696798